GPHB5

Across TCGA pan-cancer cohorts, GPHB5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GPHB5 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GPHB5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPHB5 expression acts as an unfavorable survival marker.

LUAD, BLCA, and PRAD are the cancer types where GPHB5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.163	0.835	<.001	42	view →
BLCA	OS	Median	III,IV	0.085	0.684	<.001	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	6	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GPHB5–LUAD (OS)

Open the LUAD breakdown →